Back to today’s briefing

Story perspectives

Adial Pharmaceuticals Patents Breakthrough Treatment for Addiction

2/13/2025

25 5

Summary

Story summary

Adial Pharmaceuticals has secured a groundbreaking U.S. patent for innovative methods in diagnosing and treating substance use disorders, issued on February 11, 2025. Their investigational drug, AD04, specifically targets individuals with the TT genotype of the serotonin transporter gene, promising to enhance recovery for those battling opioid and alcohol dependence.

1 of 1

Story summary

Adial Pharmaceuticals has secured a groundbreaking U.S. patent for innovative methods in diagnosing and treating substance use disorders, issued on February 11, 2025. Their investigational drug, AD04, specifically targets individuals with the TT genotype of the serotonin transporter gene, promising to enhance recovery for those battling opioid and alcohol dependence.